- Home
- NNY vs KOD Comparison
NNY vs KOD Comparison
Compare NNY & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NNY
- KOD
- Stock Information
- Founded
- NNY 1987
- KOD 2009
- Country
- NNY United States
- KOD United States
- Employees
- NNY N/A
- KOD N/A
- Industry
- NNY Investment Managers
- KOD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NNY Finance
- KOD Health Care
- Exchange
- NNY Nasdaq
- KOD Nasdaq
- Market Cap
- NNY 163.0M
- KOD 186.3M
- IPO Year
- NNY N/A
- KOD 2018
- Fundamental
- Price
- NNY $8.26
- KOD $5.53
- Analyst Decision
- NNY
- KOD Hold
- Analyst Count
- NNY 0
- KOD 5
- Target Price
- NNY N/A
- KOD $3.50
- AVG Volume (30 Days)
- NNY 50.9K
- KOD 405.3K
- Earning Date
- NNY 01-01-0001
- KOD 11-26-2024
- Dividend Yield
- NNY 4.04%
- KOD N/A
- EPS Growth
- NNY N/A
- KOD N/A
- EPS
- NNY N/A
- KOD N/A
- Revenue
- NNY N/A
- KOD N/A
- Revenue This Year
- NNY N/A
- KOD N/A
- Revenue Next Year
- NNY N/A
- KOD N/A
- P/E Ratio
- NNY N/A
- KOD N/A
- Revenue Growth
- NNY N/A
- KOD N/A
- 52 Week Low
- NNY $7.58
- KOD $2.08
- 52 Week High
- NNY $8.87
- KOD $7.77
- Technical
- Relative Strength Index (RSI)
- NNY 27.40
- KOD 77.30
- Support Level
- NNY $8.33
- KOD $3.73
- Resistance Level
- NNY $8.45
- KOD $5.39
- Average True Range (ATR)
- NNY 0.08
- KOD 0.35
- MACD
- NNY -0.01
- KOD 0.10
- Stochastic Oscillator
- NNY 3.70
- KOD 86.77
About NNY Nuveen New York Municipal Value Fund
Nuveen New York Municipal Value Fund Inc is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from both regular federal and New York state income taxes, by investing primarily in a portfolio of municipal obligations issued by state and local government authorities within the state of New York or certain U.S. territories.
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is KSI-301, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD.